medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2010, Number 1

<< Back Next >>

Arch Med Urg Mex 2010; 2 (1)

Safety and efficacy of calcium polystyrene sulfonate in hyperkalemia in patients with chronic renal disease

Lagunas-Muñoz J, Méndez-Durán A, Pérez-Grovas H, Argueta-Villamar V, Mejía-Saldívar M, Molina-Pérez A, Revilla-Beltri J

Language: Spanish
References: 14
Page: 12-16
PDF size: 109.06 Kb.


ABSTRACT

Background: Patients with chronic renal disease present with hyperkalemia, which depending on their levels is associated with heart rhythm disorders potentially lethal. Calcium polystyrene sulfonate (resincalcio) is useful for reducing and controlling serum potassium levels without the need for invasive procedures. Objective: To evaluate the efficacy and safety of calcium polystyrene sulfonate in patients with chronic kidney disease stages 4 and 5 and hyperkalemia. Methods: Prospective clinical study. It made clinical history and was determine blood chemistry baseline and 7 days post-treatment. With figures of potassium from 5.6 to 7.0 mEq/L and 7.1 to 7.5 mEq/L, was administered orally polystyrene at 30 and 45 g. Results: We included 44 women and 62 men, all adults, 55 years (± 18) age and weight of 66 kg (± 15). There was a difference in baseline serum potassium (6.91 ± 0.67 mEq/L) to the end (5.28 ± 0.77 mEq / L) p ≤ 0.0001, t = 22.01 and was not observed with calcium, sodium and chloride, p = 0.26, p = 0.32, p = 0.37. There were no serious adverse events or abnormalities in liver function tests. Conclusions: Calcium polystyrene sulfonate decreased serum potassium levels effectively and safety, thereby maintaining this group of patients out of cardiac risk for hyperkalemia.


REFERENCES

  1. Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC. Primer on kidney disease. National Kidney Foundation. Elsevier Saunders 4th edition 2005: 110-119.

  2. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. Journal American Society of Nephrology 1995; 6: 1134-1142.

  3. Charytan D, Goldfarb D. Indications for hospitalization of patients with hyperkalemia. Archives of Internal Medicine 2000; 160 (12): 1605-1611.

  4. Brenner and Rector’s. El riñón. Tratado de Nefrología. Edit. Elsevier Saunders. Séptima edición; 2005: 998-1025.

  5. Rose B, Post T. Trastornos de los electrolitos y del equilibrio ácido base. Editorial Marbán. 5a. Edition; 2001: 888-920.

  6. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002; 92 (Supl 1): 33-40.

  7. Kamel S, Wei C. Controversial issues in the treatment of hyperkalemia. Nephrology Dialysis and Transplantation 2003; 18: 2215-2218.

  8. Méndez-Durán A, Mendoza-Gaitán A. Causas de ingreso a un hospital de segundo nivel. Revista de Especialidades Médico Quirúrgicas. 2001; 6 (3): 22-24.

  9. Renal Data System: USRDS Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. 2003.

  10. Nirupama P, Michael A. Management of hyperkalemia in dialysis patients. Seminars in Dialysis 2007; 20 (5): 431-439.

  11. Gifford J, Rutsky E, Kirk K, McDaniel H. Control of serum potassium during fasting in patients with end stage renal failure. Kidney 1989; 35: 90-94.

  12. Owen W, Lew N, Liu Y, Lowrie E, Lazarus J. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing haemodialysis. New England Journal Medicine 1993; 329: 1001-1006.

  13. Blumberg A, Roser W, Zehnder C, Müller BJ. Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrology Dialysis Transplantation 1997; 12: 1629-1634.

  14. Gross P. Hyperkalemia: again. Nephrology Dialysis Transplantation 2004; 19: 2163-2166.




2020     |     www.medigraphic.com